Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.msard.2020.102196 http://scihub22266oqcxt.onion/10.1016/j.msard.2020.102196 32480326!7228888!32480326     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32480326&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mult+Scler+Relat+Disord 2020 ; 42 (ä): 102196 Nephropedia Template TP {{tp|p=32480326|t=2020. Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?|pdf=|usr=}}{{32480326}} gab.com Text Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19 JO: Mult Scler Relat Disord http://www.kidney.de/pget.php?&tw=1&pmid=32480326 #FOAvip BACKGROUND: The Coronavirus (COVID-19), (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) has been spreading worldwide since its first identification in China. It has been speculated that patients with comorbidities and elderly patients could be at high risk for the pandemic reasoned respiratory insufficiency and death. At first, it was thought that the patients who use immunmodulator therapy could be even at higher risks of disease complications. However, it has been also speculated about that using immunmodulators could be an advantage for the clinical prognosis. Therefore, several immunmodulators are currently being tested as potential treatment for COVID-19. METHODS: In this paper we report on a patient that has been treated with type 1 interferon for multiple sclerosis who developed COVID-19. RESULTS: Despite using immunmodulator, the symptoms of the patient at hospitalization were mild and he did not show elevated D-dimer, and there was no lymphopenia. He was discharged to home-quarantine with no symptoms. DISCUSSION: This report supports the idea of using type 1 interferon in the treatment could be effective in COVID-19 affected patients. Twit Text FOAVip Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19 ????Mult Scler Relat Disord http://www.kidney.de/pget.php?&tw=1&pmid=32480326 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32480326 #FOAvip English Wikipedia <ref>{{Cite pmid|32480326}}</ref> Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19? #MMPMID32480326 Gemcioglu E; Davutoglu M; Ozdemir EE; Erden A Mult Scler Relat Disord 2020[Jul]; 42 (ä): 102196 PMID32480326show ga BACKGROUND: The Coronavirus (COVID-19), (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) has been spreading worldwide since its first identification in China. It has been speculated that patients with comorbidities and elderly patients could be at high risk for the pandemic reasoned respiratory insufficiency and death. At first, it was thought that the patients who use immunmodulator therapy could be even at higher risks of disease complications. However, it has been also speculated about that using immunmodulators could be an advantage for the clinical prognosis. Therefore, several immunmodulators are currently being tested as potential treatment for COVID-19. METHODS: In this paper we report on a patient that has been treated with type 1 interferon for multiple sclerosis who developed COVID-19. RESULTS: Despite using immunmodulator, the symptoms of the patient at hospitalization were mild and he did not show elevated D-dimer, and there was no lymphopenia. He was discharged to home-quarantine with no symptoms. DISCUSSION: This report supports the idea of using type 1 interferon in the treatment could be effective in COVID-19 affected patients. |Adult[MESH] |Anti-Bacterial Agents/therapeutic use[MESH] |Antimalarials/therapeutic use[MESH] |Azithromycin/therapeutic use[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/complications/diagnostic imaging/drug therapy/*physiopathology[MESH] |Cough/etiology[MESH] |Humans[MESH] |Hydroxychloroquine/therapeutic use[MESH] |Immunologic Factors/*therapeutic use[MESH] |Interferon-beta/*therapeutic use[MESH] |Length of Stay[MESH] |Male[MESH] |Multiple Sclerosis/complications/*drug therapy[MESH] |Pandemics[MESH] |Pneumonia, Viral/complications/diagnostic imaging/drug therapy/*physiopathology[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH]Are type 1 interferons treatment in Multiple Sclerosis as a potential (epmc).pdf DeepDyve Pubget Overpricing